Dexamethasone for treatment of severe COVID-19, a surprise?

Dexamethasone for treatment of severe COVID-19, a surprise?

Bibliographic Details
Main Author:	Hany Hasan Elsayed
Format:	Article
Language:	English
Published:	SpringerOpen 2020-09-01
Series:	The Cardiothoracic Surgeon
Subjects:	COVID-19 ARDS Dexamethasone
Online Access:	http://link.springer.com/article/10.1186/s43057-020-00032-1

Similar Items

Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial
by: Abu Taiub Mohammed Mohiuddin Chowdhury, et al.
Published: (2022-04-01)

Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report
by: Jennifer Jacobson, et al.
Published: (2021-01-01)

Impact of Dexamethasone and Inhaled Nitric Oxide on Severe Acute Kidney Injury in Critically Ill Patients with COVID-19
by: Mickaël Bobot, et al.
Published: (2022-10-01)

Study find that COVID ARDS was associated with a low risk for possible or proven PCP: still true after dexamethasone use
by: Patrick M. Honore, et al.
Published: (2022-02-01)

Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?
by: Vasiliki Romanou, et al.
Published: (2021-06-01)

Dismal Survival in COVID-19 Patients Requiring ECMO as Rescue Therapy after Corticosteroid Failure
by: Sebastian Voicu, et al.
Published: (2021-11-01)

Persistent hiccups after treatment of COVID-19 with dexamethasone: A case report
by: Sajad Karampoor, et al.
Published: (2021-01-01)

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
by: Eduardo Pérez-Alba, et al.
Published: (2021-10-01)

Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
by: Sabna Kotta, et al.
Published: (2021-08-01)

A comparative study of the efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe COVID-19 disease
by: Praveen B Gautam, et al.
Published: (2021-12-01)

Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
by: Jan Maláska, et al.
Published: (2021-03-01)

A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone
by: Shukun Hong, et al.
Published: (2023-05-01)

Dexamethasone as a Treatment of COVID-19
by: Abdullah Alkattan, et al.
Published: (2020-12-01)

The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19
by: Heloísa Antoniella Braz-de-Melo, et al.
Published: (2021-04-01)

Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS
by: Funda Terzi, et al.
Published: (2022-09-01)

Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
by: Olivier Hermine, et al.
Published: (2022-04-01)

Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
by: Alexander Hooftman, et al.
Published: (2021-01-01)

Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19
by: Ameet A. Chimote, et al.
Published: (2023-03-01)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
by: Fabrice Camou, et al.
Published: (2022-09-01)

Dexamethasone use and insulin requirements in coronovirus-19 (COVID-19) infection stratified by Hemoglobin A1c
by: Caitlyn Gordon, et al.
Published: (2023-04-01)

Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan
by: Yi-Hsuan Lai, et al.
Published: (2023-12-01)

Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort study
by: Shu-Min Lin, et al.
Published: (2023-03-01)

Immuno-Modulatory Effects of Dexamethasone in Severe COVID-19—A Swedish Cohort Study
by: Sana Asif, et al.
Published: (2023-01-01)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
by: Zarębska-Michaluk D, et al.
Published: (2021-07-01)

Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trial
by: Zahra Habibi Dastenae, et al.
Published: (2022-09-01)

Impact of dexamethasone use to prevent from severe COVID-19-induced acute kidney injury
by: Arthur Orieux, et al.
Published: (2021-07-01)

Calming the Storm: A review of corticosteroid use in severely ill COVID-19 patients on mechanical ventilation
by: Tran Dinh, et al.
Published: (2021-12-01)

Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study
by: Sébastien Rubin, et al.
Published: (2024-02-01)

Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom
by: Luigino Calzetta, et al.
Published: (2021-04-01)

High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis
by: José María Mora-Luján, et al.
Published: (2021-09-01)

The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients
by: Lina Souan, et al.
Published: (2022-10-01)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
by: Rahul Gupta
Published: (2022-04-01)

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial
by: Keivan Ranjbar, et al.
Published: (2021-04-01)

Epidural Abscesses as a Complication of Interleukin-6 Inhibitor and Dexamethasone Treatment in a Patient with COVID-19 Pneumonia: A Case Report
by: Valdis Ģībietis
Published: (2023-04-01)

Dexamethasone induced Sino-orbital Mucormycosis in a Patient Infected with COVID-19
by: Masoud Mardani, et al.
Published: (2022-01-01)

Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia?
by: Khin Zar Li Aung, et al.
Published: (2021-12-01)

Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
by: Lucia Gozzo, et al.
Published: (2020-11-01)

Pulmonary embolism after dexamethasone treatment for COVID-19: a case report
by: Hidenori Takahashi, et al.
Published: (2022-03-01)

COVID-19 and HBOT: A conceptual standpoint
by: Gaurab Ghosh
Published: (2020-01-01)

Acute Respiratory Distress Syndrome (ARDS) Management Severe COVID-19
by: Helen Yudi Irianto, et al.
Published: (2023-07-01)